Objective
The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need.
The over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections. The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted.
Fields of science
Call for proposal
IMI-JU-06-2012
See other projects for this call
Coordinator
151 85 Sodertaelje
Sweden
See on map
Participants (38)
3584 CX Utrecht
See on map
1200 Bruxelles / Brussel
See on map
50937 Koeln
See on map
87000 Limoges
See on map
08036 Barcelona
See on map
Participation ended
25030 BESANCON CEDEX
See on map
38124 Braunschweig
See on map
75654 Paris
See on map
2000 Antwerpen
See on map
1211 Geneve
See on map
3703 CD Zeist
See on map
79106 Freiburg
See on map
Participation ended
1011 Lausanne
See on map
Participation ended
6525 XZ Nijmegen
See on map
BS10 5NB Bristol
See on map
Participation ended
38041 GRENOBLE
See on map
WC1A 1DG LONDON
See on map
2340 Beerse
See on map
41071 Sevilla
See on map
97159 Pointe-à-Pitre Pointe-à-Pitre
See on map
581 83 Linkoping
See on map
10561 Athina
See on map
72074 Tuebingen
See on map
17489 Greifswald
See on map
69622 Villeurbanne Cedex
See on map
3015 GD Rotterdam
See on map
08036 Barcelona
See on map
28046 MADRID
See on map
64239 Tel Aviv
See on map
1649-016 Lisboa
See on map
7270 Davos
See on map
20122 Milano
See on map
75014 Paris
See on map
8006 Zurich
See on map
75011 PARIS
See on map
07054 Parsippany
See on map
CT13 9NJ Sandwich
See on map
1050 Bruxelles / Brussel
See on map